ESMO 2018 | Improving responses to immunotherapy in NSCLC

Victor Moreno

Victor Moreno, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores avenues for overcoming resistance to immunotherapy in cancer patients, and highlights a major advancement in precision oncology at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Moreno discusses the outcomes from a recent clinical trial (NCT02383212), involving the combination of cemiplimab and radiotherapy in non-small cell lung cancer (NSCLC) patients, to demonstrate the ongoing efforts to limit resistance to immunotherapy. Dr Moreno also draws attention to a fascinating clinical trial investigating larotrectinib – a targeted therapy for patients with TRK fusions.

Share this video